Fountain Therapeutics

Executive Summary

Fountain Therapeutics is a private biotech company leveraging artificial intelligence and machine learning to discover first-in-class therapeutics for age-associated diseases. Founded in 2018 and headquartered in San Francisco, the company has developed proprietary AI/ML platforms that integrate in vitro and in vivo screening to identify novel drug targets and lead compounds. Its primary focus is on skin atrophy and skeletal muscle atrophy—two age-related conditions with significant unmet medical needs. By combining computational biology with experimental validation, Fountain aims to accelerate the development of therapies that address the underlying mechanisms of aging. Although Fountain is still in early stages with no disclosed pipeline details or funding rounds, its AI-driven approach positions it within the rapidly growing field of computational drug discovery. The company's lead programs represent first-in-class candidates for skin atrophy and a novel target for muscle atrophy, suggesting potential differentiation in the competitive landscape. Near-term progress will depend on advancing these programs through preclinical proof-of-concept studies and securing financing to support development. With a strong scientific foundation in aging biology, Fountain Therapeutics could emerge as a key player in the longevity therapeutics space if it successfully validates its platform and advances its pipeline toward clinical trials.

Upcoming Catalysts (preview)

• H2 2026Preclinical proof-of-concept data for lead skin atrophy program50% success
• H1 2026Series A financing round announcement70% success
• FY 2026Pharmaceutical partnership for skeletal muscle atrophy program40% success